New Zealand Markets open in 1 hr 51 mins

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
648.51+6.68 (+1.04%)
As of 04:00PM EST. Market open.
Currency in USD

Valuation measures

Market cap (intra-day) 5N/A
Enterprise value 3N/A
Trailing P/E N/A
Forward P/E 1N/A
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue 3N/A
Enterprise value/EBITDA 7N/A

Trading information

Stock price history

Beta (5Y monthly) 0.19
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 3686.62
52-week low 3441.00
50-day moving average 3606.65
200-day moving average 3556.67

Share statistics

Avg vol (3-month) 3758.98k
Avg vol (10-day) 3609.79k
Shares outstanding 5104.69M
Implied shares outstanding 6N/A
Float 899.73M
% held by insiders 12.85%
% held by institutions 187.02%
Shares short (14 Nov 2021) 41.61M
Short ratio (14 Nov 2021) 41.9
Short % of float (14 Nov 2021) 41.79%
Short % of shares outstanding (14 Nov 2021) 41.49%
Shares short (prior month 14 Oct 2021) 41.76M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sep 2021

Profitability

Profit margin 52.38%
Operating margin (ttm)53.85%

Management effectiveness

Return on assets (ttm)22.61%
Return on equity (ttm)51.09%

Income statement

Revenue (ttm)13.36B
Revenue per share (ttm)126.60
Quarterly revenue growth (yoy)50.50%
Gross profit (ttm)4.46B
EBITDA 7.47B
Net income avi to common (ttm)7B
Diluted EPS (ttm)35.13
Quarterly earnings growth (yoy)93.80%

Balance sheet

Total cash (mrq)5.79B
Total cash per share (mrq)55.35
Total debt (mrq)2.7B
Total debt/equity (mrq)15.64
Current ratio (mrq)3.71
Book value per share (mrq)115.54

Cash flow statement

Operating cash flow (ttm)5.94B
Levered free cash flow (ttm)3.45B